BACKGROUND AND OBJECTIVES: Adherence to evidence-based guidelines in gastric cancer is low. We aimed to evaluate adherence to National Comprehensive Cancer Network (NCCN) Guidelines for gastric cancer at both patient- and hospital-levels and examine associations between guideline adherence and treatment outcomes, including overall survival (OS). METHODS: We applied stage-specific, annual NCCN Guidelines (2004-2015) to patients with gastric cancer treated with curative-intent within the National Cancer Database and compared characteristics of patients who did and did not receive guideline-adherent care. Hospitals were evaluated by guideline adherence rate. We identified associations with OS through multivariable Cox regression. RESULTS: Of 37 659 patients included, 32% received NCCN Guideline-adherent treatment. OS was significantly associated with both guideline adherence (51 months for patients receiving guideline-adherent treatment vs. 22 for patients receiving nonadherent treatment, p < 0.001). Treatment at a hospital with higher adherence was associated with longer OS (21 months for patients treated at lowest adherence quartile hospitals vs. 37 months at highest adherence quartile hospitals, p < 0.001), regardless of type of treatment received. CONCLUSIONS: Guideline-adherent treatment was strongly associated with longer median OS. Guideline adherence should be used as a benchmark for focused quality improvement for physicians taking care of patients with gastric cancer and institutions at large.
BACKGROUND AND OBJECTIVES: Adherence to evidence-based guidelines in gastric cancer is low. We aimed to evaluate adherence to National Comprehensive Cancer Network (NCCN) Guidelines for gastric cancer at both patient- and hospital-levels and examine associations between guideline adherence and treatment outcomes, including overall survival (OS). METHODS: We applied stage-specific, annual NCCN Guidelines (2004-2015) to patients with gastric cancer treated with curative-intent within the National Cancer Database and compared characteristics of patients who did and did not receive guideline-adherent care. Hospitals were evaluated by guideline adherence rate. We identified associations with OS through multivariable Cox regression. RESULTS: Of 37 659 patients included, 32% received NCCN Guideline-adherent treatment. OS was significantly associated with both guideline adherence (51 months for patients receiving guideline-adherent treatment vs. 22 for patients receiving nonadherent treatment, p < 0.001). Treatment at a hospital with higher adherence was associated with longer OS (21 months for patients treated at lowest adherence quartile hospitals vs. 37 months at highest adherence quartile hospitals, p < 0.001), regardless of type of treatment received. CONCLUSIONS: Guideline-adherent treatment was strongly associated with longer median OS. Guideline adherence should be used as a benchmark for focused quality improvement for physicians taking care of patients with gastric cancer and institutions at large.
Authors: Michelle R Ju; James-Michael Blackwell; Herbert J Zeh; Adam C Yopp; Sam C Wang; Matthew R Porembka Journal: Ann Surg Oncol Date: 2021-02-10 Impact factor: 5.344
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Naruhiko Ikoma; Bumyang Kim; Linda S Elting; Ya-Chen Tina Shih; Brian D Badgwell; Paul Mansfield Journal: Ann Surg Oncol Date: 2019-07-01 Impact factor: 5.344
Authors: Naruhiko Ikoma; Janice N Cormier; Barry Feig; Xianglin L Du; Jose-Miguel Yamal; Wayne Hofstetter; Prajnan Das; Jaffer A Ajani; Christina L Roland; Keith Fournier; Richard Royal; Paul Mansfield; Brian D Badgwell Journal: Cancer Date: 2018-02-02 Impact factor: 6.860
Authors: Yvette H M Claassen; Romy M van Amelsfoort; Henk H Hartgrink; Johan L Dikken; Wobbe O de Steur; Johanna W van Sandick; Nicole C T van Grieken; Annemieke Cats; Henk Boot; Anouk K Trip; Edwin P M Jansen; Elma Meershoek-Klein Kranenbarg; Jeffrey P B M Braak; Hein Putter; Mark I van Berge Henegouwen; Marcel Verheij; Cornelis J H van de Velde Journal: Ann Surg Date: 2019-12 Impact factor: 12.969
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Swee H Teh; Stephen Uong; Teresa Y Lin; Sharon Shiraga; Yan Li; I-Yeh Gong; Lisa J Herrinton; Robert A Li Journal: J Clin Oncol Date: 2021-08-02 Impact factor: 44.544
Authors: Sarah R Kaslow; Leena Hani; Greg D Sacks; Ann Y Lee; Russell S Berman; Camilo Correa-Gallego Journal: Ann Surg Oncol Date: 2022-09-19 Impact factor: 4.339